From: Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
Variable | Value |
---|---|
Demographic parameters | |
 Age (years) | 45 (±14.6) |
 Female/male, n (%) | 8 (53)/7 (47) |
 Age onset of psoriasis (years) | 23 (±15) |
 Psoriasis disease duration (years) | 18 (±12) |
 Age onset of PsA (years) | 35 (±15) |
 PsA disease duration (years) | 10 (±9.6) |
 Previous sDMARDs, n (%) | 3 (20) |
 Concomitant sDMARDs (methotrexate), n (%) | 4 (27) |
 Currently taken corticosteroids, n (%) | 1 (7) |
Clinical parameters, physician’s assessment | |
 aCCP+, n (%) | 0 |
 RF+, n (%) | 1 (7) |
 ESR (mm/h) | 27 (±11) |
 CRP (mg/L) | 19 (±10.4) |
 DAS28-ESR | 4.9 (±1) |
 DAS28-CRP | 4.7 (±0.9) |
 TJC 68 | 11.5 (±11) |
 SJC 66 | 6.9 (±7.4) |
 Dactylitis (0–20) | 1.1 (±1.8) |
 Enthesitis (0–6) | 1.6 (±1.6) |
 Nail (0–10) | 5 (±3.8) |
 PASI (0–72) | 4.5 (±4.6) |
Clinical parameters, patient-reported | |
 Stiffness (minutes) | 46 (±35.9) |
 Pain (0–10) | 5.9 (±3.1) |
 GVAS (0 − 100) | 56 (±28.6) |
 Fatigue (0–10) | 5.9 (±2.8) |
 HAQ (0–3) | 0.9 (±0.7) |
 DLQI (0–30) | 4.8 (±7.2) |
 PsAQol (0–20) | 8.6 (±5.7) |